• 1. Elusive 2-aminofuran Diels–Alder substrates for a straightforward synthesis of polysubstituted anilines?
  Ana G. Neo,Ana Bornadiego,Jesús Díaz,Stefano Marcaccini,Carlos F. Marcos Org. Biomol. Chem., 2013,11, 6546-6555
• 2. Estimating and correcting interference fringes in infrared spectra in infrared hyperspectral imaging
  Ghazal Azarfar,Ebrahim Aboualizadeh,Nicholas M. Walter,Simona Ratti,Camilla Olivieri,Alessandra Norici,Michael Nasse,Achim Kohler,Mario Giordano Analyst, 2018,143, 4674-4683
• 3. Enantiomorphic symmetry breaking in crystallization of molten sodium chlorate?
  Martin R. Ward,Gary W. Copeland,Andrew J. Alexander Chem. Commun., 2010,46, 7634-7636
• 4. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291
• 5. Enantiomeric helical TiO2 nanofibers modulate different peptide assemblies and subsequent cellular behaviors?
  Xu Jie,Deng Xu,Weili Wei RSC Adv., 2019,9, 29149-29153

• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Secondary alcohols
• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Alcohols and polyols Secondary alcohols

Latest Research Insights on Rehmapicrogenin (135447-39-1) in Chemical Biology and Medicine

Rehmapicrogenin (CAS: 135447-39-1), a bioactive compound derived from the roots of Rehmannia glutinosa, has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This compound, classified as an iridoid glycoside, exhibits a range of pharmacological properties, including anti-inflammatory, neuroprotective, and hepatoprotective effects. The growing body of literature on Rehmapicrogenin underscores its potential as a therapeutic agent for various diseases, particularly those involving oxidative stress and inflammatory pathways.

Recent studies have focused on elucidating the molecular mechanisms underlying Rehmapicrogenin's bioactivity. A 2023 study published in the Journal of Natural Products demonstrated that Rehmapicrogenin modulates the NF-κB signaling pathway, thereby reducing the production of pro-inflammatory cytokines such as TNF-α and IL-6. This finding is particularly relevant for the development of novel anti-inflammatory drugs, as chronic inflammation is implicated in numerous pathologies, including rheumatoid arthritis and neurodegenerative disorders.

In addition to its anti-inflammatory properties, Rehmapicrogenin has shown promise in neuroprotection. Research conducted by Zhang et al. (2024) revealed that the compound attenuates oxidative stress in neuronal cells by upregulating the expression of antioxidant enzymes such as superoxide dismutase (SOD) and catalase. These effects were observed in both in vitro and in vivo models of Parkinson's disease, suggesting potential applications in neurodegenerative disease therapy.

The pharmacokinetic profile of Rehmapicrogenin has also been a subject of investigation. A recent pharmacokinetic study highlighted its relatively high bioavailability and stability in plasma, which are critical factors for its development as a drug candidate. However, challenges remain in optimizing its solubility and delivery methods to enhance therapeutic efficacy.

Looking ahead, the integration of advanced technologies such as CRISPR-Cas9 and AI-driven drug design could further accelerate the development of Rehmapicrogenin-based therapeutics. Collaborative efforts between academic institutions and pharmaceutical companies are essential to translate these preclinical findings into clinical applications. The continued exploration of Rehmapicrogenin's mechanisms and potential uses will undoubtedly contribute to the advancement of chemical biology and medicine.

• 108907-00-2(Viscosic acid)
• 24205-56-9(Laksholic acid)
• 24205-55-8(Jalaric acid)
• 24205-61-6((3S)-2,3,4,7,8,8aβ-Hexahydro-4β-hydroxy-3,8β-bis(hydroxymethyl)-8-methyl-1H-3aα,7α-methanoazulene-6-carboxylic acid)
• 100045-52-1(Eudesmansaeure)
• 24393-99-5(Epilaccilaksholic acid)
• 1207095-68-8((1R,6S,7R,8S)-(-)-8-hydroxysclerosporin)
• 141040-72-4(1-Cyclohexene-1-carboxylic acid, 3-hydroxy-2,6,6-trimethyl-)
• 62218-55-7(4-Hydroxy-2,6,6-trimethylcyclohex-1-enecarboxylic acid)
• 110309-10-9(1,8-Cycloundecadiene-1-carboxylicacid, 3-hydroxy-4,4,8-trimethyl-, (1E,3R,8E)-)